Myriad myRisk® Hereditary Cancer is a 28-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.

View More by clicking this

Prolaris® measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
View More by clicking this

GeneSight analyzes how an individual’s genetic profile affects their response to 56 antidepressant medications and provides an actionable, easy to interpret report.
View More by clicking this

EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider can safely forgoing chemotherapy.
View More by clicking this

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3
View More by clicking this

myChoice® HRD is a tumor test that can be used to guide important PARP inhibitor treatment decisions. By testing for BRCA1/2 status and Genomic Instability Status, which evaluates three downstream biomarkers associated with homologous recombination deficiency (HRD), myChoice HRD is capable of identifying more appropriate patients for PARP inhibitors than other biomarker assays.
View More by clicking this

Myriad myPath® Melanoma measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.
View More by clicking this

Vectra DA logo

Vectra® DA is a multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and reproducible measure of rheumatoid arthritis (RA) disease activity.
View More by clicking this